Clinical trials will begin this fall for an advanced melanoma drug developed in a collaboration of Amgen Inc. and Merck & Co. Inc.

Amgen, in Thousand Oaks, and Merck, in Whitehouse Station, N.J., are working on talimogene laherparepvec, an investigational oncolytic immunotherapy, combined with MK-3475, an investigational immunotherapy.

“Talimogene laherparepvec has shown encouraging Phase 3 clinical results as a monotherapy in patients with metastatic melanoma,” said Dr. David Chang, vice president of global development at Amgen, in a prepared statement.

Shares of Amgen fell 71 cents, less than 1percent, to $115.07 on the Nasdaq.